Literature DB >> 26386785

Heart failure in low- and middle-income countries: background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF).

Hisham Dokainish1, Koon Teo2, Jun Zhu2, Ambuj Roy2, Khalid Al-Habib2, Ahmed ElSayed2, Lia Palileo2, Patricio Lopez Jaramillo2, Kamilu Karaye2, Khalid Yusoff2, Andres Orlandini2, Karen Sliwa2, Charles Mondo2, Fernando Lanas2, Prabhakar Dorairaj2, Mark Huffman2, Amr Badr2, Mohamed Elmaghawry2, Albertino Damasceno2, Emilie Belley-Cote2, Karen Harkness2, Alex Grinvalds2, Robert McKelvie2, Salim Yusuf2.   

Abstract

BACKGROUND: Although heart failure (HF) has been referred to as a global epidemic, most HF information comes from high-income countries, with little information about low-income countries (LIC) and middle-income countries (MIC) in Africa, Asia, the Middle East, and South America, which make up the majority of the world's population.
METHODS: The INTERnational Congestive Heart Failure Study is a cohort study of 5,813 HF patients enrolled in 108 centers in 16 LIC and MIC. At baseline, data were recorded on sociodemographic and clinical risk factors, HF etiology, laboratory variables, management, and barriers to evidence-based HF care at the patient, physician, and system levels. We sought to enroll consecutive and consenting patients ≥18 years of age with a clinical diagnosis of HF seen in outpatient clinics (2/3 of patients) or inpatient hospital wards (1/3 of patients). Patients were followed up at 6 and 12 months post-enrollment to record clinical status, treatments, and clinical outcomes such as death and hospitalizations. In the 5,813 enrolled HF patients, the mean age was 59 ± 15 years, 40% were female, 62% had a history of hypertension, 30% had diabetes, 21% had prior myocardial infarction, 64% were recruited from outpatient clinics, 36% lived in rural areas, and 29% had HF with preserved left ventricular ejection fraction.
CONCLUSIONS: This unique HF registry aims to systematically gather information on sociodemographic and clinical risk factors, etiologies, treatments, barriers to evidence-based care, and outcomes of HF in LIC and MIC. This information will help improve the management of HF globally.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26386785     DOI: 10.1016/j.ahj.2015.07.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Expanding the global borders of heart failure: the SHOP and PEOPLE studies.

Authors:  Muthiah Vaduganathan; Scott D Solomon
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

Review 3.  The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.

Authors:  Ken Lee Chin; Marina Skiba; Andrew Tonkin; Christopher M Reid; Danny Liew; Henry Krum; Ingrid Hopper
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Epidemiology and aetiology of heart failure.

Authors:  Boback Ziaeian; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2016-03-03       Impact factor: 32.419

5.  Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.

Authors:  Mark Loeb; Hisham Dokainish; Antonio Dans; Lia M Palileo-Villanueva; Ambuj Roy; Kamilu Karaye; Jun Zhu; Yan Liang; Fastone Goma; Albertino Damasceno; Khalid F AlHabib; Gerald Yonga; Charles Mondo; Wael Almahmeed; Arif Al Mulla; Salim Yusuf
Journal:  Am Heart J       Date:  2019-03-11       Impact factor: 4.749

6.  Heart Failure Awareness Day: A Tribute to the Genius Carlos Chagas.

Authors:  Evandro Tinoco Mesquita; Aurea Lucia Alves de Azevedo Grippa de Souza; Salvador Rassi
Journal:  Arq Bras Cardiol       Date:  2019-08-08       Impact factor: 2.000

7.  A Fast and Validated HPLC Method for Simultaneous Determination of Dopamine, Dobutamine, Phentolamine, Furosemide, and Aminophylline in Infusion Samples and Injection Formulations.

Authors:  Fuchao Chen; Baoxia Fang; Sicen Wang
Journal:  J Anal Methods Chem       Date:  2021-02-27       Impact factor: 2.193

Review 8.  Efficacy and Safety of Traditional Chinese Medicine Injections for Heart Failure With Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Shanshan Lin; Qingyang Shi; Zhao Ge; Yangxi Liu; Yawen Cao; Ying Yang; Zhiqiang Zhao; Yingfei Bi; Yazhu Hou; Shuai Wang; Xianliang Wang; Jingyuan Mao
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.